REFILE-FDA: Data suggests AstraZeneca drug may increase death rate

April 10, 2015 12:51 PM

17 0

April 10 (Reuters) - AstraZeneca Plc's diabetes drug Onglyza appears to be associated with an increased rate of death, according to a review of data published by the U.S. Food and Drug Administration on Friday.

While the primary clinical trial results did not show a statistically significant increase in the rate of death, a more detailed analysis examining only patients who took Onglyza suggests "a significantly increased risk of all-cause mortality," FDA staff said in their review.

Read more

To category page